PT-141 + Oxytocin
One half is an approved drug. Almost nobody buying it fits the approval.
PT-141 is the rarest thing on this site, a peptide that cleared full FDA review. It was approved for one condition in one population, and the people buying it online are mostly outside both. Oxytocin is added for the emotional side and has almost no controlled evidence for it.
Wanting and closeness, treated as two problems.
Most treatments for sexual difficulty work on blood flow. PT-141 does not. It acts in the brain, on the circuits that govern desire itself, which is why it reaches people the blood flow drugs do not.
Oxytocin is added for a different layer. It is the hormone released during touch, and research associates it with trust, attachment and emotional closeness rather than with drive.
The argument is that desire and connection are separate things, and that treating one without the other leaves half the problem. It is a reasonable division and the second half has far less behind it than the first.
Compounding pharmacies sell the pair in a single preparation, sometimes with a blood flow drug added as a third component.[5] That is prescribed care rather than a research chemical purchase, and it is a different route from the vials sold online.
Four benefits, and how well each one holds up.
The top row is stronger than anything else on this site. The bottom two are weaker than most of it. Same page, same vial.
Three questions, answered before anything else.
A real approval, and a narrow one.
PT-141 is bremelanotide. The FDA approved it as Vyleesi in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women.[1] It cleared full review on the back of RECONNECT, two identical Phase 3 trials running 24 weeks in around 1,250 premenopausal women.[2] A 52-week extension followed in 684 of them, with no deaths and no new safety signals.[13]
The improvements were statistically solid and small. Desire scores rose 0.35 points more than on a dummy injection, and distress scores fell 0.33 points more.[6] One assessment notes the absolute effect sizes were modest and raises concerns about selective outcome reporting.[6]
There is also no head-to-head trial against flibanserin, the other approved drug for the same condition.[14] Sources disagree on enrollment, quoting both 1,267 and 1,247.
Now read who that covers.
One row is covered. The people buying vials online are overwhelmingly in the rows beneath it.
That does not make the approval irrelevant. It establishes that the compound reaches the brain, does what it claims, and passed a safety review no other peptide on this site has passed. It is evidence the mechanism is real.
It is not evidence for a man buying a vial, and almost every page selling one quotes it as though it were.
Approved for childbirth, sold for closeness.
Oxytocin is a real hormone with real approved uses, and they are inducing labour and supporting breastfeeding. Its sexual and emotional applications are described in the literature as largely experimental.[3]
What exists is suggestive. Research associates it with trust, empathy and attachment, and it is released naturally during touch and sex.[3] The published clinical material for sexual difficulty is mostly case reports, including one describing an elderly man treated for long-standing anorgasmia.[7]
One case report is a starting point for research rather than a basis for a purchase. No controlled trial supports oxytocin for desire, arousal or relationship satisfaction, and none supports it alongside PT-141.
One thing is unknown rather than merely untested. How the brain's oxytocin receptors respond to repeated outside dosing over long periods has not been characterised.[4]
A study cited by name that we cannot find.
A vendor page selling this combination cites a 2024 study in Psychoneuroendocrinology, describing stronger bonding behaviour and sustained sexual motivation from the two compounds together than from either alone.[8]
It gives a journal and a year. No authors, no title, no identifier. We could not locate it.
That does not mean it does not exist. Journals publish a great deal and our searching is not exhaustive. It does mean the single strongest claim made for this stack is one a reader cannot verify, on a page selling the product.
We are flagging it rather than repeating it. If the study exists and someone sends us the identifier, this page gets updated.
Melanotan II is the compound PT-141 came from.
Bremelanotide was developed out of melanotan II research. Melanotan II hit melanocortin receptors broadly, producing tanning, sexual arousal, appetite suppression and cardiovascular effects together. Bremelanotide was refined to keep the sexual effects and drop the rest.[9]
The rights were split in a 2008 settlement, with Palatin keeping bremelanotide and returning melanotan II.[10] One went through fifteen years of trials to approval. The other never did.
PT-141 should not be taken alongside melanotan II or any other melanocortin agonist. They act on overlapping receptors, so effects compound unpredictably, and no clinical data supports the combination.[11]
Melanotan II carries documented harms of its own, including a case of severe muscle breakdown with kidney injury, mole darkening, prolonged painful erections and melanoma case reports. Regulators in the UK, Australia and the United States have issued warnings.[9]
Both are sold on the same vendor pages, often side by side. We track 64 in-stock melanotan II listings and 70 for PT-141.[12]
Grey-market melanotan II vials have also been tested and found short. Breindahl and colleagues measured actual peptide content at between roughly 43 and 88 percent of what the label claimed.[15] Nobody has published the equivalent test on PT-141 vials.
The premixed vial is nearly four times the parts.
This pairing is sold ready-mixed. One in-stock listing we track combines the two in a single vial at $119.00, split roughly two parts PT-141 to one part oxytocin.[12]
Bought separately the two come to $32.07 at the cheapest in-stock listings. The blend is about 3.7 times that.
Vial sizes differ, so this is not a like-for-like comparison. It is what a buyer faces at checkout, and the gap is the largest of any blend on this site. The CJC pairing and Semax with Selank both come in cheaper premixed than separate.
A three-compound version adding VIP is listed at $179.00 and shows no stock.[12]
One approved route, and several that are not.
Vyleesi is the only approved form of bremelanotide, and the approval covers one condition in one population. Compounded PT-141 prepared against a patient-specific prescription is a recognised route and is not FDA-approved for any indication.[5] Research vials sold online are neither.
Serious adverse events were not reported at therapeutic doses in the Phase 3 trials, and the approval process required extensive safety data.[4] That is a stronger safety position than anything else on this site.
It does not transfer to everyone. The label excludes pregnancy and breastfeeding, and cardiovascular risk is assessed individually in populations the trials did not cover.[3]
Anyone whose desire has dropped has a reason to have hormone levels checked before concluding a compound has failed. Very low testosterone in either sex, or depleted estrogen, creates a background that may not respond.[6] That is a conversation for a doctor.
What people ask about this stack
Is PT-141 FDA approved?
Yes, as Vyleesi, approved in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. That is the only approved use anywhere, and it is the only full FDA approval held by any compound covered on this site. It has not been approved for men, for postmenopausal women, or for any route other than injection under the skin.
Does PT-141 work for men?
The evidence suggests PT-141 does something in men, and it stops short of approval. In men who had not responded to blood flow drugs, a Phase 2 study reported roughly a third responding against about one in eleven on a dummy injection. No Phase 3 trial was run in men, so the regulatory answer is that it has not been established. PT-141 acts on desire in the brain rather than on blood flow, so it addresses a different problem from the erection drugs.
What does adding oxytocin do?
Nobody has measured it. Oxytocin's approved uses are inducing labour and supporting breastfeeding, and its sexual and emotional applications are described in the literature as largely experimental. The published material for sexual difficulty is mostly case reports. No controlled trial supports oxytocin for desire or relationship satisfaction, and none supports the combination with PT-141.
Can PT-141 be taken with melanotan II?
Sources are explicit that it should not be. The two act on overlapping melanocortin receptors, so effects compound unpredictably, and no clinical data supports the combination. Bremelanotide was in fact developed out of melanotan II research, refined to keep the sexual effects and drop the tanning and other receptor activity. Melanotan II also carries documented harms including a case of severe muscle breakdown with kidney injury, and regulators in three countries have issued warnings about it.
Is the premixed version worth it?
The premixed vial costs nearly four times the parts. One in-stock blend listing combines the two at $119.00, against $32.07 for the cheapest separate vials. Vial sizes differ so it is not like-for-like. The gap is still the largest of any blend covered here, and other blends on this site come in cheaper premixed than separate rather than dearer.
How does PT-141 compare to kisspeptin?
PT-141 and kisspeptin work on different systems. PT-141 acts on melanocortin receptors and targets desire directly. Kisspeptin sits at the top of the hormone chain that produces testosterone, so it addresses a hormonal cause rather than the desire circuit itself. Kisspeptin remains investigational with no approval anywhere, and running the two together has its own page. Compare against the other stacks.
What this page is built on
- 01Bremelanotide, drug monograph. Trade name Vyleesi, melanocortin receptor agonist, subcutaneous, prescription only in the US, ATC code G02CX05. Elimination half-life 2.7 hours, subcutaneous bioavailability approximately 100 percent. Encyclopaedia entry citing FDA DailyMed.
- 02Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials. Obstetrics and Gynecology, 2019;134(5):899-908. PMID 31599840, DOI 10.1097/AOG.0000000000003500. Two identical 24-week double-blind placebo-controlled trials, Studies 301 and 302. Basis for FDA approval as Vyleesi, June 2019.
- 03Comparison of PT-141 and oxytocin. Source for oxytocin's approved uses being childbirth and breastfeeding with sexual and emotional uses described as largely experimental, for PT-141 acting centrally rather than on blood flow, and for the caution that combining them warrants medical supervision.
- 04Source for no serious adverse events being reported at therapeutic doses in the Phase 3 trials, and for oxytocin receptor sensitivity under repeated external dosing not being fully characterised.
- 05Compounded combination preparations. Source for compounding pharmacies supplying PT-141 with oxytocin, and with a PDE5 inhibitor as a third component, against patient-specific prescriptions; and for compounded bremelanotide not being FDA-approved for any indication.
- 06Source for the RECONNECT desire-domain improvement of 0.35 points and distress reduction of 0.33 points against placebo, for the note that absolute effect sizes were modest and that selective outcome reporting concerns have been raised, for the Phase 2 male response figures in PDE5 non-responders of roughly 34 percent against 9 percent, and for the note that very low testosterone or depleted estrogen may prevent a response.
- 07Ishak, Berman et al., 2008. Case report of off-label intranasal oxytocin for a four-year history of anorgasmia in an 82-year-old married man with co-morbid diabetes and coronary artery disease.
- 08A vendor page selling this combination cites a 2024 study in Psychoneuroendocrinology reporting stronger pro-social bonding and sustained sexual motivation from co-administration than from either compound alone. No authors, title or identifier are given and we could not locate the study.
- 09PT-141 compared with melanotan II. Source for bremelanotide being a refined derivative engineered to shed broad receptor activity; for melanotan II having no approval for any indication; and for its documented harms including a published case of rhabdomyolysis with renal dysfunction, mole darkening, prolonged erections and melanoma case reports, plus regulatory warnings in the UK, Australia and the United States.
- 10Origin and rights history. Melanotan II was too broad in its receptor activity for a sexual health drug, producing tanning, nausea, appetite suppression and cardiovascular effects. The parties settled in 2008 with Palatin retaining bremelanotide, returning melanotan II rights and paying $800,000.
- 11Explicit guidance that PT-141 should not be combined with melanotan II or other melanocortin agonists, on the grounds that receptor overlap compounds safety effects and no clinical data supports the combination.
- 13Simon JA, Kingsberg SA et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics and Gynecology, 2019. DOI 10.1097/AOG.0000000000003514. 52-week open-label extension in 684 participants who completed the core phase. No deaths across the whole RECONNECT programme and no new safety signals. Funded by Palatin Technologies and AMAG Pharmaceuticals.
- 14Evidence review noting no head-to-head trial against flibanserin, the other approved drug for the same indication; no completed Phase 3 programme in men; and long-term safety data extending only to the trial periods rather than to lifetime use.
- 15Breindahl and colleagues, analysis of grey-market melanotan II vials. Measured peptide content ranged from roughly 43 to 88 percent of the labelled amount. Same source records published case reports linking melanotan II to melanoma, ischemic priapism, rhabdomyolysis, renal infarction and posterior reversible encephalopathy syndrome, and attributes the rhabdomyolysis case to Nelson and colleagues, Clinical Toxicology, 2012.
- 12Peptide Decoding vendor pricing data, 18 September 2026. Lowest in-stock single-compound listings: PT-141 $22.07 across 70 listings, oxytocin $10.00 across 42, melanotan II $21.05 across 64. One in-stock premixed listing combining PT-141 and oxytocin at $119.00 in a two-to-one ratio by weight, and a three-compound version adding VIP at $179.00 showing no stock.